Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lonardi

Showing results (31-40 of 115) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patientsA A Argyriou, R Velasco, C Briani, et al.
European Journal of Neurology|December 21, 2012
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective studyA A Argyriou, C Briani, G Cavaletti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2019
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trialsS Cascinu, D Poli, A Zaniboni, et al.
British Journal of Cancer|March 14, 2007
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)E Franceschi, G Cavallo, S Lonardi, et al.
ESMO Open|August 13, 2025
Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approachesM C de Grandis, I Baraibar, O Prior, et al.
British Journal of Cancer|January 17, 2013
Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancerR Bertorelle, M Briarava, E Rampazzo, et al.
British Journal of Cancer|June 4, 2014
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumabE Zulato, F Bergamo, A De Paoli, et al.
ESMO Open|April 11, 2025
Claudin 18.2: a promising actionable target in biliary tract cancersV Angerilli, D Sacchi, M Rizzato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2010
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trialR Labianca, A Sobrero, L Isa, et al.
Neurology|December 14, 2011
Association of innate immune activation with latent Epstein-Barr virus in active MS lesionsJ S Tzartos, G Khan, A Vossenkamper, et al.
Pageof 12

Showing results (31-40 of 115) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patientsA A Argyriou, R Velasco, C Briani, et al.
European Journal of Neurology|December 21, 2012
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective studyA A Argyriou, C Briani, G Cavaletti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2019
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trialsS Cascinu, D Poli, A Zaniboni, et al.
British Journal of Cancer|March 14, 2007
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)E Franceschi, G Cavallo, S Lonardi, et al.
ESMO Open|August 13, 2025
Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approachesM C de Grandis, I Baraibar, O Prior, et al.
British Journal of Cancer|January 17, 2013
Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancerR Bertorelle, M Briarava, E Rampazzo, et al.
British Journal of Cancer|June 4, 2014
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumabE Zulato, F Bergamo, A De Paoli, et al.
ESMO Open|April 11, 2025
Claudin 18.2: a promising actionable target in biliary tract cancersV Angerilli, D Sacchi, M Rizzato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2010
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trialR Labianca, A Sobrero, L Isa, et al.
Neurology|December 14, 2011
Association of innate immune activation with latent Epstein-Barr virus in active MS lesionsJ S Tzartos, G Khan, A Vossenkamper, et al.
Pageof 12